Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
Steven Nissen, MD, Cleveland Clinic, explains an ACC.22 late-breaking trials that uses an mRNA drug to greatly reduce lipoprotein A. #ACC22

VIDEO: Use of mRNA drug to lower lipoprotein(a) by up to 98%

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

Older LAAO patients, especially women, face a higher risk of complications

Researchers explored data from the National Inpatient Sample, sharing their findings in the American Journal of Cardiology.

Thumbnail

DOACs an effective substitute for VKAs after AFib patients undergo bioprosthetic valve replacement

Direct oral anticoagulants are noninferior to vitamin K antagonists when treating this important patient population, researchers reported. 

Evolocumab

Evolocumab limits adverse cardiovascular outcomes among PCI patients

Data from the FOURIER trial helped clinicians learn more about this popular PCSK9 inhibitor.

Thumbnail

USPSTF shares updated recommendations on statin use to prevent CVD

The public comment period for these recommendations ends on March 21.

Ticagrelor alone after DAPT lowers bleeding risk among heart attack patients undergoing PCI

Researchers examined data from the TWILIGHT study to track how different treatment strategies can impact 12-month PCI outcomes. 

LAAC or DOACs? How treatment strategies for AFib impact long-term outcomes

The new analysis provided an update on data from the PRAGUE-17 trial. 

Thumbnail

DOACs underprescribed among high-risk AFib patients

The study found that frail patients with AFib are less likely to be treated with DOAC therapy.

Displaying 233 - 240 of 290

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup